The fundamental goal of AMNOG is to find a balance between innovation and affordability. Particularly for new active ingredients, prices should be found in close correlation to the patient-relevant additional benefit. From 2014, 1.4 billion euros will have to be saved through price negotiations because the three-year price moratorium and the compulsory discount on patent-protected medicines, which has been increased to 16 %, will then expire.

Read more